Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias.

The Indian biopharma company expects to enroll patients from mid-September.

Masupirdine is a selective, brain penetrant and orally active, chemical entity.

Its late-stage study to be held in the US and Europe will involve nearly 387 patients. It is expected to be wrapped up in approximately 36 months with results likely to be released by the end of 2024.

Venkat Jasti — CEO of Suven Life Sciences said: “Progression of SUVN-502 (Masupirdine) into Phase 3 clinical development is a significant achievement and milestone in enhancing our clinical pipeline. Our lead molecules address niche areas of cognitive impairment associated with neurodegenerative disorders.”

Masupirdine had been through a phase 2 study featuring 564 patients with moderate Alzheimer’s disease.

The mid-stage trial did not meet its primary endpoint. However, following an in-depth analysis of the data and dialogue with opinion leaders, Suven Life Sciences is said to have decided on a new clinical trial for the treatment of aggression and agitation in Alzheimer’s type dementias.

  Alzheimer’s Disease, Dementia, Masupirdine, neurodegenerative disorders, Suven Life Sciences, SUVN-502, USA, Venkat Jasti